Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

All eyes on Saint Regis Mohawk Tribe in contentious patent case

Tangible IP's Latest IP Market Update

Senators question Allergan CEO on tribe patent deal

Senators question Allergan CEO on tribe patent deal

Does Allergan's Saint Regis Mohawk Tribe transactional move rip off consumers? - The IPKat

Supreme Court's Arthrex decision creates more review for patent owners — and more questions - Medical Design and Outsourcing

Trump attacks drug companies for high prices, weighs options to curb monopolies

Allergan Gains Another Approval for Botox Amid Patent Controversy Over Restasis - Xtalks

Allergan plc

A handful of Allergan's top shareholders want to bring back the old CEO as chairman

Allergan does patent deal for Restasis with Native American tribe

Alex Levine, Author at School of Pharmacy